Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy

Author： Driscoll James  

Publisher： Springer Publishing Company

ISSN： 1776-2596

Source： Targeted Oncology, Vol.5, Iss.4, 2010-12, pp. : 281-289

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Proteasome Inhibition: A Novel Approach to Anticancer Therapy

By Paul G. Richardson   Teru Hideshima   Kenneth C. Anderson  

American Journal of Cancer, Vol. 3, Iss. 5, 2004-01 ,pp. : 271-279

Adis International

Access to resources Recommend Favorite

Discovery of P3971 an Orally Efficacious Novel Anticancer Agent Targeting HIF-1 and STAT3 Pathways

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 9, 2013-11 ,pp. : 1460-1466

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Anti-Cancer Strategy in Bone Tumors by Targeting Molecular and Cellular Modulators of Bone Resorption

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 3, Iss. 3, 2008-11 ,pp. : 178-186

Bentham Science Publishers

Access to resources Recommend Favorite

The Ubiquitin-Proteasome Pathway an Emerging Anticancer Strategy for Therapeutics: A Patent Analysis

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 10, Iss. 2, 2015-05 ,pp. : 201-213

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics

By  

Current Cancer Therapy Reviews, Vol. 6, Iss. 4, 2010-11 ,pp. : 262-282

Bentham Science Publishers

Access to resources Recommend Favorite